

Table 11. Ocular and non-ocular adverse events related to study drug and/ or procedure (Safety set)

Preferred term, n (%)	Ranibizumab N=115	Ranibizumab + Laser N=120	Laser N=110
Ocular AEs, total	28 (24.3)	27 (22.5)	20 (18.2)
Eye pain	12 (10.4)	10 (8.3)	11 (10.0)
Conjunctival hemorrhage	8 (7.0)	9 (7.5)	0
Conjunctival hyperemia	8 (7.0)	4 (3.3)	6 (5.5)
Foreign body sensation in eyes	4 (3.5)	7 (5.8)	2 (1.8)
Eye discharge	3 (2.6)	3 (2.5)	1 (0.9)
Visual impairment	3 (2.6)	2 (1.7)	0
Eye irritation	2 (1.7)	0	2 (1.8)
Eyelid oedema	2 (1.7)	3 (2.5)	1 (0.9)
Lacrimation increased	2 (1.7)	3 (2.5)	1 (0.9)
Vision blurred	2 (1.7)	1 (0.8)	2 (1.8)
Corneal erosion	1 (0.9)	1 (0.8)	0
Eye pruritus	1(0.9)	1 (0.8)	2 (1.8)
Intraocular pressure increased	1 (0.9)	1 (0.8)	0
Ocular hyperaemia	1 (0.9)	1 (0.8)	0
Photophobia	1 (0.9)	1 (0.8)	0
Ocular discomfort	0	1 (0.8)	2 (1.8)
Non-ocular AEs, total	9 (7.8)	3 (2.5)	2 (1.8)
Pulmonary embolism	2 (1.7)	0	0
Arterial thrombosis limb	1 (0.9)	0	0
Arthralgia	1 (0.9)	0	0
Back pain	1 (0.9)	0	0
Dyspnoea	1 (0.9)	0	0
Hypertension	1 (0.9)	0	1 (0.9)
Hypoglycaemia	1 (0.9)	0	0
Influenza	1 (0.9)	0	0
Influenza like illness	1 (0.9)	0	0
Intestinal obstruction	1 (0.9)	0	0
Nausea	1 (0.9)	0	0
Rhinorrhoea	1 (0.9)	0	0
Urticaria	1 (0.9)	0	0
Anxiety	0	1 (0.8)	0
Coronary artery occlusion	0	1 (0.8)	0
Dizziness	0	1 (0.8)	0
Hypertensive crisis	0	0	1 (0.9)

AEs, adverse events